Baicheng Pharmaceutical announced recently that the innovative drug BIOS0635-048 tablets independently developed by the company have obtained a clinical trial approval notice from the State Drug Administration. BIOS0635-048 tablets are novel small molecule inhibitors independently developed by the company and intended for the treatment of various solid tumors.

Baicheng Pharmaceutical announced recently that the innovative drug BIOS0635-048 tablets independently developed by the company have obtained a clinical trial approval notice from the State Drug Administration. BIOS0635-048 tablets are novel small molecule inhibitors independently developed by the company and intended for the treatment of various solid tumors.